



Oregon Prescription Drug Affordability Board Regular Meeting

Wednesday, August 19, 2026

Minutes approved by the board on September 16, 2026

Web link to the meeting video: <https://youtu.be/5GDmlQ9Hh7c>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20260819-PDAB-document-package.pdf>

Call to order: Chair Shelley Bailey called the meeting to order at 8:03 a.m.

Roll call:

Present: Chair Shelley Bailey, Vice Chair Dan Hartung, Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, Noelle Redmond

Absent: John Murray

Board declarations of conflict of interest and meetings with entities or individuals related to board activities: Chris Laman provided a statement. View this agenda item at video minute [00:01:00](#).

Approval of board minutes: Chair Bailey approved by consensus the July 15, 2026, minutes as shown on [Pages 2-3](#) of the agenda materials. View this agenda item at video minute [00:02:19](#).

PDAB program update: Sarah Young, PDAB executive director, provided a program update. View this agenda item at video at minute [00:02:44](#).

General public comment: Primo Castro of BIO and Terrell Sweat of Johnson & Johnson spoke to the board during the general public comment period. The board received one written general comment, which is posted on the [PDAB website](#). View this agenda item at video minute [00:08:35](#).

Drug review public comment:

The board received 17 written drug review comments, which are posted on the [PDAB website](#). Ten people spoke during the drug review public comment period. See table below for speaker names and affiliations. View this agenda item at video minute [00:14:53](#).

Table 1: Drug review public comment speakers

Speaker name	Affiliation	Drug
Patrick Altieri	Patient	Ocrevus
Lisa Carman	Genentech	Ocrevus
Arcadi Kolchak	AbbVie	Skyrizi
Chris Herbine	Johnson & Johnson	Tremfya
Kelly Cleary	Food Allergy Research and Education	Xolair



Speaker name	Affiliation	Drug
Susan Powell	Patient	Xolair
Jenna Riemenschneider	Asthma and Allergy Foundation of America	Xolair
Dr. Joshi Shyam	Oregon Health and Science University	Xolair
Lisa Carman	Genentech	Xolair

Drug review: Ocrevus, Skyrizi, Tremfya, and Xolair: Cortnee Whitlock, PDAB program and senior policy analyst, presented the drug review reports, followed by board discussion. She reviewed the 2026 drug review roadmap on [Page 5](#) of the agenda materials while Sarah Young, executive director, reviewed the [statewide reference document for 2024 data](#). Board members discussed the drug review reports for [Ocrevus](#), [Skyrizi](#), [Tremfya](#), and [Xolair](#). Find links to all the drug review documents discussed at the board meeting on [Page 6](#) of the agenda materials. View this agenda item at video minute [00:47:46](#).

Announcements: Chair Bailey announced the next board meeting will be September 16, 2026, beginning at 8 a.m. Pacific time. View this agenda item at video minute [02:08:28](#).

Adjournment: Chair Bailey adjourned the meeting at 10:15 a.m. with all board members in agreement. View this agenda item at video minute [02:08:37](#).